Hester Biosciences Limited has never executed a stock split on its equity shares since its initial public listing and historical trading records. The company has maintained its core share face value structure, choosing instead to reward long-term shareholders through consistent annual dividend distributions and retaining earnings to fund capital-intensive biological manufacturing expansions and international subsidiary growth in Nepal and Africa.